Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Acer Therapeutics Inc (NQ: ACER )

3.020 USD -0.050 (-1.63%)
Official Closing Price Updated: 7:57 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Acer Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Acer Therapeutics to Participate in Needham Virtual Healthcare Conference
From GlobeNewswire News Releases
Notice of Settlement of Derivative Suits
From GlobeNewswire News Releases
Thinking about buying stock in Acer Therapeutics, Cemtrex, Comstock Mining, Marker Therapeutics, or Strongbridge Biopharma?
InvestorsObserver issues critical PriceWatch Alerts for ACER, CETX, LODE, MRKR, and SBBP. 
From PR Newswire
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Diseas
From GlobeNewswire News Releases
Thinking about buying stock in Check Cap, Shaw Comm., Acer Therapeutics, Intec Pharma, or GenMark Diagnostics?
InvestorsObserver issues critical PriceWatch Alerts for CHEK, SJR, ACER, NTEC, and GNMK. 
From PR Newswire
Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Acer Therapeutics to Participate in March Virtual Investor Conferences
From GlobeNewswire News Releases
Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions
Targeting a pre-NDA meeting with FDA in Q2 2021 
From GlobeNewswire News Releases
Thinking about buying stock in Acer Therapeutics, Zomedica, Novan, Atossa Therapeutics, or Tellurian?
InvestorsObserver issues critical PriceWatch Alerts for ACER, ZOM, NOVN, ATOS, and TELL. 
From PR Newswire
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for t
From GlobeNewswire News Releases
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for t
From ACCESSWIRE
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders
Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021 
From GlobeNewswire News Releases
Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden
Authors report that celiprolol may have a protective effect in COL3A1-positive vEDS patients 
From GlobeNewswire News Releases
Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Schubert Firm Investigating Possible Breaches of Fiduciary Duty by Acer Therapeutics Inc. Officers and Directors
Schubert Jonckheer & Kolbe LLP is investigating potential shareholder derivative claims on behalf of stockholders of Acer Therapeutics Inc. (NYSE: ACER) related to the company's statements about its... 
From PR Newswire
ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
ACER LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acer Therapeutics Inc. 
From Business Wire News Releases
Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital
From GlobeNewswire News Releases
NASDAQ: ACER Shareholder Notice: Update in Lawsuit Against Acer Therapeutics Inc.
San Diego, CA -- (SBWIRE) -- 09/18/2020 -- A lawsuit is pending for certain investors in Acer Therapeutics Inc. (NASDAQ: ACER) shares and NASDAQ: ACER stockholders should contact the Shareholders... 
From SBWire - Latest Press Releases
Acer Therapeutics to Virtually Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
Shareholder Alert: Robbins LLP Announces the Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss
Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc. (NASDAQ: ACER) may face damages caused by a pending securities class action. Acer Therapeutics is a pharmaceutical company... 
From Business Wire News Releases
Acer Therapeutics Investors Who Have Held Their Stock Continuously Since at Least September 25, 2017 Are Encouraged to Contact Kehoe Law Firm, P.C.
From GlobeNewswire News Releases
Lifshitz Law Firm, P.C. Announces Investigation of Acer Therapeutics, Inc. (ACER), Advanced Disposal Services, Inc. (ADSW), Apyx Medical Corporation (APYX), Honeywell International Inc. (HON), Immunom
From PR Newswire
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Acer Therapeutics Inc. (ACER)
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets,... 
From Business Wire News Releases
Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study
From GlobeNewswire News Releases
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Acer Therapeutics Inc. Investors (ACER)
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. (“Acer” or the “Company”) (NASDAQ: ACER) concerning whether the board... 
From Business Wire News Releases
Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
Expanded pipeline with addition of emetine for COVID-19; progressed ACER-001, osanetant and EDSIVO™ programs; and entered into stock purchase agreement with Lincoln Park Capital 
From GlobeNewswire News Releases
Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health
From GlobeNewswire News Releases
Acer Therapeutics Announces Common Stock Purchase Agreement for up to $15 million with Lincoln Park Capital
From GlobeNewswire News Releases
Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA’s Office of New Drugs
Office of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO™ 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.